Pulnovo Medical trial cuts heart failure clinical worsening risk by 51
Clinical outcomes from 264 patients demonstrate a 51 reduction in clinical worsening risk alongside a 35 5 decrease in recurrent events during the trial
SHANGHAI, Sept. 3, 2026 - Pulnovo Medical has unveiled the results of the PADN-HF-PH trial, which reveals a 51% reduction in the risk of clinical worsening for patients with pulmonary arterial hypertension associated with left heart disease. Published in The New England Journal of Medicine and presented at the European Society of Cardiology Congress, this multicenter, randomized controlled trial involving 264 patients offers new hope for heart failure management.
The PADN procedure, a minimally invasive therapy, has been shown to modify the overall disease burden, improve functional capacity and quality of life, and decrease the annualized rate of recurrent clinical events by 35.5%.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
